Form 4: Prime Medicine Executive Ann Lee L. Lee Acquires 80,416 Shares Via Option Vesting

Ann L. Lee, Chief Technical Officer of Prime Medicine, Inc., acquired 80,416 shares of common stock through the vesting of a stock option on May 17, 2024, following the achievement of a performance milestone.

Summary

• On May 17, 2024, Ann L. Lee, the Chief Technical Officer of Prime Medicine, Inc., acquired 80,416 shares of common stock.
• This acquisition occurred due to the vesting of a stock option initially granted on October 27, 2021.
• The vesting was triggered by the achievement of a performance milestone, as determined by the board of directors of the Issuer.
• The exercise price of the stock option is $3.67.
• Following the transaction, Lee directly owns 160,832 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The vesting of options indicates the achievement of a performance milestone, which is generally a positive sign. However, it's a routine filing and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The achievement of a performance milestone triggered the vesting of stock options, indicating progress for Prime Medicine.
• The vesting of options incentivizes the Chief Technical Officer, aligning her interests with the company's success.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• Shareholders may view the vesting of options as a positive sign, indicating progress towards company goals.
• Employees may be motivated by the achievement of performance milestones and the potential for future option vesting.

Key Dates